Sean O'Neill |
And thank you for talking about such an important topic thats really relevant right now to patients
Eligibility criteria for NHS-funded Wegovy typically require: BMI 35 kg/m (or 32.5 kg/m for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) BMI 30 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, or obstructive sleep apnoea) Additionally, NICE TA875 specifies that treatment should be provided within a specialist weight management service and is time-limited
Meanwhile, 10.3% of patients who took the highest dose of Eli Lilly's pill stopped treatment due to side effects, compared with around 2.6% of people in a placebo group
INCRETIN-BASED THERAPIES FDA APPROVED FOR WEIGHT MANAGEMENT The FDA has approved several incretin hormonebased pharmacotherapeutic agents, including liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide, tirzepatide, and orforglipron
But beyond the headlines, what do these treatments actually do